BRIEF published on 08/12/2024 at 13:05, 1 year 4 months ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 1 year 4 months ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 1 year 5 months ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
PRESS RELEASE published on 07/08/2024 at 23:15, 1 year 5 months ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 1 year 6 months ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
PRESS RELEASE published on 06/20/2024 at 13:00, 1 year 6 months ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 1 year 6 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
PRESS RELEASE published on 06/19/2024 at 13:00, 1 year 6 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 1 year 6 months ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
PRESS RELEASE published on 06/18/2024 at 13:00, 1 year 6 months ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 12/22/2025 at 08:05, 57 minutes ago Tocvan Begins Trenching Material for the Pilot Mine and Pushes Ahead With Infrastructure Development
Published on 12/20/2025 at 00:30, 2 days 8 hours ago Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 2 days 11 hours ago GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 2 days 14 hours ago Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 2 days 18 hours ago Northern Superior Announces Closing of the Arrangement
Published on 12/22/2025 at 08:51, 11 minutes ago XTPL selects Estonia-based Tech Group to manufacture future Delta Printing System devices
Published on 12/22/2025 at 08:45, 16 minutes ago AT&S appoints Gerrit Steen as new CFO and streamlines its Executive Board
Published on 12/22/2025 at 08:30, 31 minutes ago Original-Research: Mexedia S.p.a. SB (von GBC AG): Buy
Published on 12/22/2025 at 08:30, 32 minutes ago Anemoi enters into binding Sale and Purchase Agreement to acquire Trasna
Published on 12/22/2025 at 08:30, 32 minutes ago Diginex Limited Executes Landmark Deal to Build Supply Chain Compliance Leader
Published on 12/19/2025 at 08:30, 3 days ago Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 07:00, 3 days 2 hours ago EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
Published on 12/18/2025 at 18:30, 3 days 14 hours ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 17:45, 3 days 15 hours ago Cie du Bois Sauvage : Cancellation of own shares
Published on 12/18/2025 at 16:31, 3 days 16 hours ago In Brazil, ENGIE Fully Commissions Serra do Assuruá, Its Largest Wind Complex Worldwide
